Angiotensin (1-7) dosing & administration
The heart-friendly peptide that balances your blood pressure and protects your cardiovascular system
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
100 mcg/kg
Frequency
Once daily after each chemotherapy session
Duration
Up to 6 chemotherapy cycles
In a cancer trial, this dose was injected under the skin after chemo to help protect platelet counts. A higher 300 mcg/kg dose was also tested but did not work better. [4]
Timing
Best time to take
Use Angiotensin (1-7) at the same time each day for optimal results. Consistency in timing helps maintain stable levels and maximize therapeutic benefits. Follow your healthcare provider's specific instructions.
With food?
Angiotensin (1-7) can generally be used with or without food. If you experience any discomfort, try taking it with a light meal. Follow specific guidance from your healthcare provider.
If stacking
Angiotensin (1-7) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Angiotensin (1-7) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Angiotensin (1-7) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: As directed by healthcare provider—rotate sites if applicable
Maintain a consistent schedule for optimal results with Angiotensin (1-7). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Hypotension (Low Blood Pressure), Dizziness or Lightheadedness, Injection Site Reactions, Headache
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Angiotensin (1-7)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Angiotensin (1-7) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- NSAIDs (High-Dose) — May reduce effectiveness and increase kidney injury risk
- Potassium Supplements — Risk of dangerous potassium elevation (hyperkalemia)
- Certain Diuretics — May compound electrolyte imbalances and blood pressure effects
Published research
What the studies show
Bilgin E, et al. · 2026
Ang-(1-7) demonstrated protective effects in joint inflammation by modulating the renin-angiotensin system locally. The peptide's ability to reduce inflammatory markers and protect tissue function extends therapeutic potential beyond cardiovascular conditions.
Aazar RFM, et al. · 2026
SGLT2 inhibitors combined with RAAS blockade demonstrated superior cardiorenal protection through complementary mechanisms. The Ang-(1-7) protective axis works synergistically with these modern therapies, reducing heart failure hospitalization and slowing kidney disease progression without additional safety concerns.
Tapia-Martínez JA, et al. · 2026
Ang-(1-7) levels were downregulated in chronic kidney disease, but exogenous H2S administration restored protective Ang-(1-7) pathway function. This restored Mas receptor expression, reduced oxidative stress, and prevented vascular dysfunction while improving hypertension management.
Pham H, Schwartz BM, Delmore JE, et al. · 2013
Patients received angiotensin-(1-7) subcutaneously at 100 mcg/kg or 300 mcg/kg following chemotherapy for up to six cycles; the 100 mcg/kg dose reduced Grade 3-4 thrombocytopenia with no drug-related safety issues.
Self WH, Shotwell MS, Gibbs KW, et al. · 2022
Patients with severe COVID-19 received TXA-127 (angiotensin 1-7) intravenously at 0.5 mg/kg once daily, intended for up to 10 days; no serious adverse events were attributed to the drug.
Head to head
Angiotensin (1-7) compared
Want the full picture?
The complete Angiotensin (1-7) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.